Multifocal Motor Neuropathy
Conditions
Brief summary
This prospective longitudinal study will follow participants with Multifocal Motor Neuropathy over time and collect data on their clinical outcomes, quality of life, and use of health care resources. Participants will follow their regular visit schedule with their treating physician, except for an optional second visit occurring 7 to 14 days after the start of the study to collect biomarker data. No IMP will be administered.
Interventions
None listed
Sponsors
argenx
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Is at least the local legal age of consent for clinical studies when signing the ICF * Is capable of providing signed informed consent and complying with protocol requirements * Has an existing or new diagnosis of MMN made by a neuromuscular specialist or neurologist
Exclusion criteria
* Is currently participating in any clinical study with an IMP * Has other medical conditions that could affect the assessment of MMN
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To characterize MMN patient profiles for participants | up to 61 months |
| To assess the MMN disease management and disease course | up to 61 months |
| To assess outcome measures specific to MMN disease and their evolution over time | up to 61 months |
| To estimate the burden of MMN on participants' quality of life | up to 61 months |
| To estimate the economic burden for participants with MMN | up to 61 months |
| To collect data on relevant disease biomarkers | up to 61 months |
Countries
Australia, Austria, Belgium, Bulgaria, Canada, China, Czechia, Denmark, France, Germany, Italy, Japan, Latvia, Poland, Romania, Serbia, Spain, Sweden, United Kingdom, United States
Outcome results
None listed